Malignancy Consortium News Today

Operator: Good day, and welcome to the Inovio Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

INO earnings call for the period ending June 30, 2023.

Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European...

Miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Screening people with HIV for precancerous anal cell changes and treating them early cuts the risk of anal cancer by more than half, according to results from the ANCHOR study published June 16 in the New England Journal of Medicine.

A large clinical trial of people living with HIV has found that treating anal precancerous growths known as high-grade squamous intraepithelial lesions, or HSIL, reduces the chance that anal cancer will develop by more than half.

/PRNewswire/ -- Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and...

ANCHOR data support screening and treatment for anal HSIL in those ages 35 and up

For the first time, researchers have shown that treating anal HSIL lesions prevents cancer progression in HIV.